|
1
|
Stroun M, Maurice P, Vasioukhin V, Lyautey
J, Lederrey C, Lefort F, Rossier A, Chen XQ and Anker P: The origin
and mechanism of circulating DNA. Ann NY Acad Sci. 906:161–168.
2000.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Agassi R, Czeiger D, Shaked G, Avriel A,
Sheynin J, Lavrenkov K, Ariad S and Douvdevani A: Measurement of
circulating cell-free DNA levels by a simple fluorescent test in
patients with breast cancer. Am J Clin Pathol. 143:18–24.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Boddy JL, Gal S, Malone PR, Harris AL and
Wainscoat JS: Prospective study of quantitation of plasma DNA
levels in the diagnosis of malignant versus benign prostate
disease. Clin Cancer Res. 11:1394–1399. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kamat AA, Baldwin M, Urbauer D, Dang D,
Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL,
et al: Plasma cell-free DNA in ovarian cancer: An independent
prognostic biomarker. Cancer. 116:1918–1925. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jahr S, Hentze H, Englisch S, Hardt D,
Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood
plasma of cancer patients: Quantitations and evidence for their
origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665.
2001.PubMed/NCBI
|
|
8
|
Ziegler A, Zangemeister-Wittke U and
Stahel RA: Circulating DNA: A new diagnostic gold mine? Cancer
Treat Rev. 28:255–271. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ryan BM, Lefort F, McManus R, Daly J,
Keeling PW, Weir DG and Kelleher D: A prospective study of
circulating mutant KRAS2 in the serum of patients with colorectal
neoplasia: Strong prognostic indicator in postoperative follow up.
Gut. 52:101–108. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Anker P, Mulcahy H, Chen XQ and Stroun M:
Detection of circulating tumour DNA in the blood (plasma/serum) of
cancer patients. Cancer Metastasis Rev. 18:65–73. 1999.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Devonshire AS, Whale AS, Gutteridge A,
Jones G, Cowen S, Foy CA and Huggett JF: Towards standardisation of
cell-free DNA measurement in plasma: Controls for extraction
efficiency, fragment size bias and quantification. Anal Bioanal
Chem. 406:6499–6512. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Alcaide M, Cheung M, Hillman J, Rassekh
SR, Deyell RJ, Batist G, Karsan A, Wyatt AW, Johnson N, Scott DW,
et al: Evaluating the quantity, quality and size distribution of
cell-free DNA by multiplex droplet digital PCR. Sci Rep.
10(12564)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Janku F, Huang HJ, Fujii T, Shelton DN,
Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner
RG, et al: Multiplex KRASG12/G13 mutation testing of unamplified
cell-free DNA from the plasma of patients with advanced cancers
using droplet digital polymerase chain reaction. Ann Oncol.
28:642–650. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kulasinghe A, Monkman J, Nalder M, Leary
CO, Ladwa R and Bayre KO: Transformation or progression from
adenocarcinoma to small cell lung cancer detected by serially
tracking mutations in the blood. Reports. 3(33)2020.
|
|
15
|
Roth C, Pantel K, Müller V, Rack B,
Kasimir-Bauer S, Janni W and Schwarzenbach H: Apoptosis-related
deregulation of proteolytic activities and high serum levels of
circulating nucleosomes and DNA in blood correlate with breast
cancer progression. BMC Cancer. 11(4)2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fiala C and Diamandis EP: Utility of
circulating tumor DNA in cancer diagnostics with emphasis on early
detection. BMC Med. 16(166)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Goldshtein H, Hausmann MJ and Douvdevani
A: A rapid direct fluorescent assay for cell-free DNA
quantification in biological fluids. Ann Clin Biochem. 46:488–494.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chiminqgi M, Moutereau S, Pernet P, Conti
M, Barbu V, Lemant J, Sacko M, Vaubourdolle M and Loric S: Specific
real-time PCR vs. fluorescent dyes for serum free DNA
quantification. Clin Chem Lab Med. 45:993–995. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Park K, Woo M, Kim JE, Ahn JH, Jung KH,
Roh J, Gong G and Kim SB: Efficacy of assessing circulating
cell-free DNA using a simple fluorescence assay in patients with
triple-negative breast cancer receiving neoadjuvant chemotherapy: A
prospective observational study. Oncotarget. 9:3875–3886.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yu SC, Lee SW, Jiang P, Leung TY, Chan KC,
Chiu RW and Lo YM: High-resolution profiling of fetal DNA clearance
from maternal plasma by massively parallel sequencing. Clin Chem.
59:1228–1237. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
López-Otín C and Matrisian LM: Emerging
roles of proteases in tumour suppression. Nat Rev Cancer.
7:800–808. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Rumore P, Muralidhar B, Lin M, Lai C and
Steinman CR: Haemodialysis as a model for studying endogenous
plasma DNA: Oligonucleosome-like structure and clearance. Clin Exp
Immunol. 90:56–62. 1992.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Stroun M, Anker P, Maurice P, Lyautey J,
Lederrey C and Beljanski M: Neoplastic characteristics of the DNA
found in the plasma of cancer patients. Oncology. 46:318–322.
1989.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Abbosh C, Birkbak NJ, Wilson GA,
Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA,
Veeriah S, Rosenthal R, et al: TRACERx consortium; PEACE
consortium: Phylogenetic ctDNA analysis depicts early-stage lung
cancer evolution. Nature. 545:446–451. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Vansteenkiste J, Wauters E, Reymen B,
Ackermann CJ, Peters S and De Ruysscher D: Current status of immune
checkpoint inhibition in early-stage NSCLC. Ann Oncol.
30:1244–1253. 2019.PubMed/NCBI View Article : Google Scholar
|
